Anti-obesity and glucose-lowering pharmacotherapies predominantly exert their actions by inducing satiety (liraglutide, setmelanotide, lorcaserin, pramlintide, sibutramine) or by inducing malabsorption of nutrients (orlistat)
Research indicates that tirzepatide may produce greater weight loss than semaglutide at equivalent stages, making it a preferred choice for some patients
Which states cover GLP-1 for obesity changes frequently
Regular monitoring and adjustments : Your hormone levels, not just weight, guide our treatment decisions
In case you missed it, California-based Kaiser Foundation Health Plan and Hospitals, which make up the insurance and facilities half of Kaiser Permanente, announced the acquisition of Geisinger, a Pennsylvania-based health system once acknowledged by President Obama for delivering high-quality care. Upon regulatory approval, Geisinger will become the first organization to join Risant Health, Kaiser Foundations newly created $5 billion subsidiary
Fourteen products, including Tepezza, indicated for thyroid eye disease, and the leukemia drug Blincyto, achieved blockbuster status in 2025